Report an error

Spotted something inaccurate in “FDA Approves Generic Dapagliflozin, Expanding Access to SGLT2 Inhibitor for Type 2 Diabetes and Heart Failure”? Tell us what’s wrong and we’ll check it against the original source.

Website

Send report Cancel

This form is for factual corrections. We read every report but cannot reply individually.